On air · 1 of 3 networks
Immix Biopharma (Nasdaq: IMMX)
- immixbio.com
- Healthcare & Life Sciences
- US
- 52 employees
Immix Biopharma (Nasdaq: IMMX)’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 21. Watch Immix Biopharma (Nasdaq: IMMX) with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 21 | Checked 31 Oct 2026 | See all 21 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 21 Oct 2026 | Collect them with the API → |
| Not checked | — |
Immix Biopharma (Nasdaq: IMMX) has 21 live LinkedIn ads. Its Facebook page had no active ads on 21 Oct 2026.
Latest ads
- LINKEDIN · IMAGERecorded 23 Sept 2026
Immx Biopharma announced new progress in its U.S. clinical trial of NXC-201 for AL Amyloidosis. 🧬 Learn how the program is advancing and what this update means for the ongoing development of this CAR-T therapy.
- LINKEDIN · IMAGERecorded 23 Sept 2026
Immx Biopharma announced new progress in its U.S. clinical trial of NXC-201 for AL Amyloidosis. 🧬 Learn how the program is advancing and what this update means for the ongoing development of this CAR-T therapy. 💉
- LINKEDIN · IMAGERecorded 23 Sept 2026
Groundbreaking therapies. Rapid progress. Major market potential. See why IMMIX Biopharma is on the radar of top biotech investors. 🔬
- LINKEDIN · IMAGERecorded 23 Sept 2026
Immix Biopharma’s innovative CAR-T therapy, NXC-201, is making significant strides in its U.S. trial for AL Amyloidosis. 🌟 Learn more about how this breakthrough treatment is advancing to higher dose levels, offering new hope for patients. 💉🧬
- LINKEDIN · IMAGERecorded 23 Sept 2026
🌟 Breakthrough Alert! 🌟 Immix Biopharma has dosed the 1st patient in the U.S. AL Amyloidosis trial with our pioneering CAR-T NXC-201 therapy! This marks a significant step forward in our mission to combat rare diseases with cutting-edge treatments. Join us as we pave the way for medical advancements and transform patient care. 🌐 Discover more about this milestone and our innovative approach.
- LINKEDIN · IMAGERecorded 23 Sept 2026
🔬 A New Era in Biopharma! 🔬 Immix Biopharma proudly announces the dosing of the 1st patient in our U.S. AL Amyloidosis trial using CAR-T NXC-201. This is a monumental leap in treating this complex condition. Be part of our journey to pioneering new therapies and improving lives. ✨ Dive into the details and see how we're making history.
6 of 21 adsSign up to see every Immix Biopharma (Nasdaq: IMMX) ad, filter by format and date, and get alerts on new ones.
See all 21 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.